Galvanize Therapeutics nets $100M, and a new CEO, to bring pulsed field ablation to lung cancer
Galvanize Therapeutics has raised $100 million in venture capital backing—and is making a change in leadership—to help energize its development of pulsed field ablation technology for use against cancer and…